Senti Biosciences (Senti Biosciences) Debt-to-EBITDA : -0.62 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Senti Biosciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Senti Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $4.28 Mil. Senti Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $32.45 Mil. Senti Biosciences's annualized EBITDA for the quarter that ended in Mar. 2024 was $-59.36 Mil. Senti Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.62.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Senti Biosciences's Debt-to-EBITDA or its related term are showing as below:

SNTI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.64 Med: -0.62 Max: -0.55
Current: -0.55

During the past 4 years, the highest Debt-to-EBITDA Ratio of Senti Biosciences was -0.55. The lowest was -0.64. And the median was -0.62.

SNTI's Debt-to-EBITDA is ranked worse than
100% of 277 companies
in the Biotechnology industry
Industry Median: 1.36 vs SNTI: -0.55

Senti Biosciences Debt-to-EBITDA Historical Data

The historical data trend for Senti Biosciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Senti Biosciences Debt-to-EBITDA Chart

Senti Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

-0.62

-0.61

-0.64

-0.61

Senti Biosciences Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial								-0.68	-0.52	-0.57	-0.56	-0.62

Competitive Comparison of Senti Biosciences's Debt-to-EBITDA

For the Biotechnology subindustry, Senti Biosciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Senti Biosciences's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Senti Biosciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Senti Biosciences's Debt-to-EBITDA falls into.

Senti Biosciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Senti Biosciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(4.128	+	33.538)	/	-61.336
	=	-0.61

Senti Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(4.278	+	32.445)	/	-59.36
	=	-0.62

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

Senti Biosciences (NAS:SNTI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Senti Biosciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Senti Biosciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Senti Biosciences (Senti Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Senti Biosciences Inc (NAS:SNTI) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Corporate Drive, First Floor, South San Francisco, CA, USA, 94080

Website

https://www.sentibio.com

Senti Biosciences Inc is a preclinical biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells.

Executives

Kanya Rajangam	officer: Chief Medical & Devt. Officer	C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Aktiengesellschaft Bayer	10 percent owner	BAYERWERK, GEBAEUDE W11, KAISER-WILHELM-ALLEE, LEVERKUSEN 2M D-51368
Susan D Berland	director	C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Timothy K Lu	director, officer: CEO and President	SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
James J. Collins	director	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Bayer World Investments B.v.	10 percent owner	ENERGIEWEG 1, MIJDRECHT P7 3641
Deborah Knobelman	officer: Chief Financial Officer	C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Herberts Curt A. Iii	officer: Chief Operating Officer	501 CANAL BLVD., POINT RICHMOND TECH CENTER, RICHMOND CA 94804
Brenda Cooperstone	director	C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Philip J Lee	officer: Chief Technology Officer	C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Edward T Mathers	director	C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Nea 15 Gp, Llc	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 15, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
New Enterprise Associates 15, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093